Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cisplatin, and capecitabine, work
in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Monoclonal antibodies, such as bevacizumab, and small molecule
tyrosine kinase inhibitors, such as lapatinib, can block tumor growth in different ways. Some
block the ability of tumor cells to grow and spread. Others find tumor cells and help kill
them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor
cells by blocking blood flow to the tumor. Lapatinib targets a specific growth receptor,
HER-2. Chemotherapy together with bevacizumab or lapatinib, in HER-2 positive tumours, may
kill more tumor cells.
PURPOSE: This randomized phase II/III trial is studying the side effects and how well giving
combination chemotherapy together with bevacizumab works compared with combination
chemotherapy alone in treating patients with previously untreated stomach cancer,
gastroesophageal junction cancer or lower oesophageal cancer that can be removed by surgery.
The feasibility study is studying the safety of adding lapatinib to chemotherapy in patients
with HER-2 positive previously untreated stomach cancer, gastroesophageal junction cancer or
lower oesophageal cancer that can be removed by surgery. The feasibility study will also
assess the feasibility of timely HER-2 testing and estimate the HER-2 positivity rate in this
patient population.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Professor David Cunningham
Collaborators:
Cancer Research UK GlaxoSmithKline Roche Pharma AG